Pre-filled syringes are single-use syringes that are pre-loaded with the medication that will be injected. It is a single dose of medicine with a needle attached by the manufacturer. As these syringes are prefilled, nurses or patients do not need to prepare the medication and pull it into the needle; instead, the appropriate dosage is already present in the barrel and is ready for speedy injection. Moreover, prefilled syringes are safer to use since they are highly accurate. Some cartridges of prefilled syringes are made to fit into self-aspirating syringes, which penetrate the skin and provide drugs without the need to press a plunger. This guarantees that doses are supplied smoothly and that injections reach the proper depth.

Market Dynamics

Increasing incidence of chronic diseases which leads to driving the demand of prefilled syringes as its treatment is expected to fuel the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention data on chronic diseases updated in July 2022, around six in ten adults in the U.S. were affected by a type of chronic disease, and over four in ten adults were affected by two or more chronic diseases. Cancer is the most common chronic disease affecting people worldwide. For instance, according to the GLOBOCAN 2020 report, the total number of people in the world affected by cancer in 2020 accounted for around 19,292,789 cases. The number is estimated to rise to 28,887,940 cases by 2040. Several types of cancer are treated with the help of novel drugs and biologics, which is expected to increase the demand for prefilled syringes over forecast period (2023-2030). Thus, the rising cancer cases across the world is expected to boost the growth of the prefilled syringes market over the forecast period.

The increasing approvals from various regulatory agencies by market players to expand product portfolio is expected to drive the market growth over the forecast period. For instance, in December 2022, Alembic Pharmaceuticals Limited, a multinational pharmaceutical company, announced that it had received final approval from the U.S. Food & Drug Administration for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe. Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of breast cancer.

Key features of the study:

• This report provides in-depth analysis of the global prefilled syringes market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global prefilled syringes market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Gerresheimer AG, Becton Dickinson and Company, West Pharmaceutical Services, Inc., Terumo Corporation, Nipro Europe Group Companies, B. Braun SE, Sanofi, GSK plc., Pfizer Inc., Bayer AG, Polymedicure, Amsino International, Inc., Leeford Healthcare Limited, Torrent Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Ypsomed AG, SOL-Millennium, and Stevanato Group S.p.A.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global prefilled syringes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prefilled syringes market

Detailed Segmentation:

• Global Prefilled Syringes Market, By Material:
  • Glass
  • Plastic/Polymer
• Global Prefilled Syringes Market, By Drug Type:
  • Biologics
    • Monoclonal Antibodies
    • Blood Products
    • Others (Erythropoietin, Therapeutic proteins, among others)
  • Vaccines
    • Conjugated Vaccines
    • Live Attenuated Vaccines
    • Recombinant Vaccines
    • Others (Virus-like particles (VLPs), Viral vector vaccines)
  • Insulin
  • Anticoagulants
  • Flush Saline Syringes
  • Others
• Global Prefilled Syringes Market, By Design:
  • Single-chamber
  • Dual-chamber
  • Multi-chambered
• Global Prefilled Syringes Market, By Product Type:
  • Staked in-needle pre-filled syringes
  • Needle-free pre-filled syringes
• Global Prefilled Syringes Market, By Usability:
  • Disposable
  • Reusable
• Global Prefilled Syringes Market, By Manufacturing Method:
  • Captive
  • Merchant
• Global Prefilled Syringes Market, By End User:
  • Hospital
  • Clinics
  • Ambulatory Surgical Centers
  • Others
• Global Prefilled Syringes Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Gerresheimer AG
  • Becton, Dickinson and Company
  • West Pharmaceutical Services, Inc.
  • Terumo Corporation
  • Nipro Europe Group Companies
  • B. Braun SE
  • Sanofi
  • GSK plc.
  • Pfizer Inc.
  • Bayer AG
  • Polymedicure
  • Amsino International, Inc.
  • Leeford Healthcare Limited
  • Torrent Pharmaceuticals Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Ypsomed AG
  • SOL-Millennium
  • Stevanato Group S.p.A.